Xilio Therapeutics Inc (NASDAQ: XLO) started the day on Thursday, with a price increase of 8.25% at $0.94, before settling in for the price of $0.87 at the close. Taking a more long-term approach, XLO posted a 52-week range of $0.49-$1.93.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 0.00% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -44.91%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 58.99%. This publicly-traded company’s shares outstanding now amounts to $43.96 million, simultaneously with a float of $20.53 million. The organization now has a market capitalization sitting at $41.23 million. At the time of writing, stock’s 50-day Moving Average stood at $1.0021, while the 200-day Moving Average is $0.9683.
Xilio Therapeutics Inc (XLO) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Xilio Therapeutics Inc’s current insider ownership accounts for 53.29%, in contrast to 16.09% institutional ownership. According to the most recent insider trade that took place on Dec 18 ’24, this organization’s 10% Owner bought 1,759,978 shares at the rate of 1.04, making the entire transaction reach 1,830,377 in total value, affecting insider ownership by 9,105,451. Preceding that transaction, on Apr 02 ’24, Company’s 10% Owner bought 485,250 for 0.76, making the whole transaction’s value amount to 368,790. This particular insider is now the holder of 7,345,473 in total.
Xilio Therapeutics Inc (XLO) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
Xilio Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 58.99% and is forecasted to reach -0.51 in the upcoming year.
Xilio Therapeutics Inc (NASDAQ: XLO) Trading Performance Indicators
Let’s observe the current performance indicators for Xilio Therapeutics Inc (XLO). It’s Quick Ratio in the last reported quarter now stands at 1.67. The Stock has managed to achieve an average true range (ATR) of 0.11. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 8.92.
In the same vein, XLO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.72, a figure that is expected to reach -0.22 in the next quarter, and analysts are predicting that it will be -0.51 at the market close of one year from today.
Technical Analysis of Xilio Therapeutics Inc (XLO)
If we take a close look at the recent performances of Xilio Therapeutics Inc (NASDAQ: XLO), its last 5-days Average volume was 1.11 million that shows progress from its year to date volume of 0.51 million. During the previous 9 days, stock’s Stochastic %D was recorded 29.85% While, its Average True Range was 0.1082.
Raw Stochastic average of Xilio Therapeutics Inc (XLO) in the period of the previous 100 days is set at 29.92%, which indicates a major fall in contrast to 39.33% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 57.43% that was lower than 104.35% volatility it exhibited in the past 100-days period.
